EDA2R/TNFRSF27/XEDAR Antibody (173111) [Alexa Fluor® 700]

• Reactivity: Hu
• Applications: WB, B/N
• Clone: 173111
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 700

EDA2R/TNFRSF27/XEDAR Antibody (173111) [Alexa Fluor® 700] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human EDA2R/TNFRSF27/XEDAR
  Met1-Glu136
  Accession # Q9HAV5
• Specificity: Detects human EDA2R/TNFRSF27/XEDAR in direct ELISAs and Western blots.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Blockade of Receptor-ligand Interaction
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for EDA2R/TNFRSF27/XEDAR Antibody (173111) [Alexa Fluor® 700]

• ectodysplasin A2 receptor
• EDA2R
• EDA-A2 receptor
• EDAA2R
• EDA-A2R
• EDAA2Rtumor necrosis factor receptor superfamily member XEDAR
• EDAR2
• TNFRSF27
• XEDAR
• XEDARTNFRSF27tumor necrosis factor receptor superfamily member 27
• X-linked ectodysplasin-A2 receptor

Background

X-linked Ectodysplasin Receptor (XEDAR), also known as EDA2R and TNFRSF27, is an approximately 45 kDa transmembrane protein in the TNF receptor superfamily (1). Mature human XEDAR consists of a 136 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 140 aa cytoplasmic domain (2). Within the ECD, human XEDAR shares 87% aa sequence identity with mouse and rat XEDAR. A 55 kDa long isoform of human XEDAR carries a 21 aa insertion in the juxtamembrane cytoplasmic domain (3). A 20 kDa fragment of the ECD can be shed by metalloprotease mediated cleavage (4). XEDAR binds selectively to the EDA-A2 variant of Ectodysplasin (EDA), while the closely related receptor EDAR binds selectively to the EDA-A1 variant (2). Other than a 2 aa deletion in its TNF-like domain, EDA-A2 is identical to EDA-A1 (2). Mutations in both EDAR and EDA are associated with hypohidrotic ectodermal dysplasia (HED), a disorder of hair, tooth, and eccrine sweat gland morphogenesis (5). XEDAR itself is strongly associated with androgenetic alopecia (male hair loss) (6). XEDAR is widely expressed, notably in embryonic basal epidermal cells and maturing hair follicles (2, 7, 8). Even though it does not contain a cytoplasmic death domain, XEDAR can associate with Fas and induce EDA-A2 dependent apoptosis (7, 9). Its transcription is directly induced by p53, and XEDAR mediated cell death is p53 dependent (7, 10). XEDAR is down‑regulated in breast, colon, and lung cancers, particularly in cases with p53 mutations (7, 11). XEDAR also plays a role in EDA‑A2 induced skeletal muscle degeneration and osteoblast differentiation (8, 12).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.